Diagnostic Imaging's Weekly Scan: November 2 — November 8

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

In a newly published review from the European Society of Urogenital Radiology (ESUR), researchers discussed the merits and limitations of PSMA PET/CT and whole-body MRI (WB-MRI) for patients with advanced prostate cancer.

In a new multicenter study published in Radiology, pre-op contrast-enhanced mammography demonstrated a 95 percent specificity rate and 83.5 percent positive predictive value for ascertaining pathologic nipple involvement with breast cancer.

In an interview with Diagnostic Imaging, Steven Rowe, MD, discussed pertinent insights from recently published molecular imaging guidelines for renal masses and the potential of 89Zr-girentuximab for clear cell renal cell carcinoma (ccRCC) detection.

New research published in Academic Radiology shows that incorporating the CT vascular sign into assessments of pulmonary nodules led to significant increases in specificity and accuracy as well as reduced false positive rates for differentiating between malignant and benign solid pulmonary nodules.

Amid the variety of new product launches this week in radiology, the Harrison.ai Open Platform reportedly emphasizes open architecture, customer ROI and single-integration access to multiple AI vendors.

Watch the video summary below of Diagnostic Imaging’s Weekly Scan.